Evaluate Vantage Homepage
Investors bite the big pharma hands that feed them
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Abbvie takes its Treg cue
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Big pharma’s biggest spenders revealed
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Medtech
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Company Events
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Pressure piles up on pamrevlumab
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Interviews
Thought CETP inhibition was dead? Think again
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.